Venetoclax: Phase II data

An open-label, dose-escalation Phase II trial in 32 AML patients showed that venetoclax led to an ORR of 19%, including

Read the full 205 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE